ArticlePharmaceutical biology2021
The anti-breast cancer property of physcion via oxidative stress-mediated mitochondrial apoptosis and immune response.
Article in Pharmaceutical biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 17 citations in OpenAlex.
- Comprehensive Review on the Toxicity of Five Main AQ Constituents from Rhubarb: Mechanisms, Challenges and Future Perspectives.Drug design, development and therapy · 2026Review
- Current status and trend of global research on the pharmacological effects of emodin family: bibliometric study and visual analysis.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Inhibition of 6-phosphogluconate dehydrogenase suppresses esophageal squamous cell carcinoma growth and enhances the anti-tumor effects of metformin via the AMPK/mTOR pathway.Molecular cancer · 2025Article
- The Activity of 1,8-Dihydroanthraquinone Derivatives in Nervous System Cancers.Molecules (Basel, Switzerland) · 2024Review
- Towards the Use of Lichens as a Source of Bioactive Substances for Topical Applications.Molecules (Basel, Switzerland) · 2024Article
- Research Progress on the Anti-Liver Cancer Mechanism and Toxicity of Rhubarb Anthraquinone.Drug design, development and therapy · 2024Review
- Review
- Therapeutic Potential of 1,8-Dihydroanthraquinone Derivatives for Breast Cancer.International journal of molecular sciences · 2023Review
- Physcion prevents induction of optic nerve injury in rats via inhibition of the JAK2/STAT3 pathway.Experimental and therapeutic medicine · 2023Article
- Natural products target glycolysis in liver disease.Frontiers in pharmacology · 2023Review
- Modulation of Hair Growth Promoting Effect by Natural Products.Pharmaceutics · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
contextPhyscion (Phy) exerts several pharmacological effects including anti-inflammatory, antioxidant, and antitumor properties.
objectiveThis study investigates the cytotoxicity and its underlying mechanisms of Phy on breast cancer. MATERIALS AND
methodsHuman breast cancer cell MCF-7 was treated with 5-400 µM Phy for 24 h, MCF-7-xenografted BALB/c nude mice and immunosuppressive mice model induced by cyclophosphamide were intraperitoneally injected with 0.1 mL/mouse normal saline (control group) and 30 mg/kg Phy every other day for 14 or 28 days, and pathological examination, ELISA and western blot were employed to investigate the Phy anti-breast cancer property
resultsIn MCF-7 cells, Phy 24 h treatment significantly reduced the cell viability at dose of 50-400 µM and 24 h, with an IC DISCUSSION AND
conclusionsThis research demonstrated that Phy has an anti-breast cancer property via the modulation of oxidative stress-mediated mitochondrial apoptosis and immune response, which provides a scientific basis for further research on its clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.